HOME

NEWS
2nd Review Meeting
10-31-2024

Today we wrapped up a successful 2nd Review Meeting for NeoVasculoStop.
A huge thank you to our Officer, Reviewers, and all Partners for their invaluable contributions and for the great presentations. Together, we’re making great strides in advancing our project’s vision and impact!

Stay tuned for more exciting results creating a brighter future!

NeoVasculoStop Hits Milestone with Top Retinopathy Inhibitors
07-31-2024

In a significant stride for retinopathy treatment, the NeoVasculoStop consortium has successfully reached the milestone of Month 30 entitled “Identification of the Two Best Inhibitors.” Correspondingly, EYE1118 has been selected as an efficient promising lead compound and EYE1090 as the follow up molecule. This achievement marks a critical phase in the project aimed at developing advanced inhibitors for targeted disease treatment.

We are optimistic about the future applications of these results in treating a complex group of diseases.

EXCITING NEWS FROM THE ARVO ANNUAL MEETING!
07-22-2024

We’re thrilled to share that Experimentica, our partner, significantly impacted the recent ARVO2024. Their presence and contributions were invaluable, making the event a huge success.
Seeing our partners thriving and driving innovation in their respective fields is always inspiring. Collaborations like these are instrumental in pushing boundaries and achieving remarkable results.
Congratulations to the Experimentica team for their outstanding performance at the ARVO2024! Looking forward to more fruitful collaborations ahead.

Overview
As our population ages and diabetes becomes more prevalent, the incidence of retinopathies is expected to rise. Existing therapies, such as eye injections, necessitate outpatient visits and may be associated with adverse effects.
We propose an oral medication that will effectively deliver any therapeutic molecule to the eye. Our approach aims to reduce adverse effects, help patients maintain their vision, lower treatment costs, and decrease the required therapeutic dose.

We aim to demonstrate the proof-of-concept of the proposed strategy by modifying inhibitors of the vascular endothelial growth factor receptor (VEGFR) that is a key mediator of angiogenesis and an established drug target for treating retinopathies.

NeoVasculoStop establishes the foundation for a new future technology. The core idea can later be applied to any other ocular disease, provided that an ocular target molecule (such as a receptor, enzyme, or channel) can be identified. We believe that the chemical properties of the medication offer significant advantages over traditional treatments. Our ambition is strongly motivated by the exceptional societal impact that the new product could have globally.
project timeline
Partners
The coordinator of the consortium is Experimentica Ltd., (EXPERIM) a Finnish contract research organization (CRO) that specializes in preclinical models of ophthalmic diseases. Vichem Ltd. (VICHEM) as a consortium member, is responsible for the design and synthesis of all the drug molecules, for the creation of a focused library of the compounds and the large-scale synthesis of the selected lead compound for in vivo studies. Semmelweis University (SE) tests the efficiency of the compounds in a retinal cell-based in vitro system, assesses the directed enrichment of the compounds in vivo in the retina, verifies the efficiency of the compounds in rodent disease models and assesses their safety and excludes their toxicity in post mortem human retinae. EMMES will receive the efficacy, safety and toxicity data derived from in vitro, in vivo experiments and safety tests on post mortem human retinae to synthesize all this information to design the phase I human clinical trial and produce all the documents that are to be submitted to the regulatory authorities so that permission for the phase I can be obtained. LC Innoconsult International (LC) manages the project in cooperation with Experimentica, furthermore ensures adequate communication, exploitation and dissemination of the achievements and project activities. READ MORE
experimentica Vichem Semmelweis Emmes Lc-Innoconsult